Safety of Semaglutide

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mark M. Smits, Daniël H. Van Raalte
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	glucagon-like peptide-1 receptor agonist (GLP-1RA) oral subcutaneous semaglutide type 2 diabetes safety Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/c006b197be31425dac88ecfb77dea26f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c006b197be31425dac88ecfb77dea26f
record_format	dspace
spelling	oai:doaj.org-article:c006b197be31425dac88ecfb77dea26f2021-11-10T15:20:17ZSafety of Semaglutide1664-239210.3389/fendo.2021.645563https://doaj.org/article/c006b197be31425dac88ecfb77dea26f2021-07-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.645563/fullhttps://doaj.org/toc/1664-2392The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide InnOvatioN for the Early diabEtes tReatment) semaglutide and are being studied in further trials and registries, including real world data studies. In the current review we discuss the occurrence of adverse events associated with semaglutide focusing on hypoglycemia, gastrointestinal side effects, pancreatic safety (pancreatitis and pancreatic cancer), thyroid cancer, gallbladder events, cardiovascular aspects, acute kidney injury, diabetic retinopathy (DRP) complications and injection-site and allergic reactions and where available, we highlight potential underlying mechanisms. Furthermore, we discuss whether effects are specific for semaglutide or a class effect. We conclude that semaglutide induces mostly mild-to-moderate and transient gastrointestinal disturbances and increases the risk of biliary disease (cholelithiasis). No unexpected safety issues have arisen to date, and the established safety profile for semaglutide is similar to that of other GLP-1RAs where definitive conclusions for pancreatic and thyroid cancer cannot be drawn at this point due to low incidence of these conditions. Due to its potent glucose-lowering effect, patients at risk for deterioration of existing DRP should be carefully monitored if treated with semaglutide, particularly if also treated with insulin. Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.Mark M. SmitsDaniël H. Van RaalteFrontiers Media S.A.articleglucagon-like peptide-1 receptor agonist (GLP-1RA)oralsubcutaneoussemaglutidetype 2 diabetessafetyDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glucagon-like peptide-1 receptor agonist (GLP-1RA) oral subcutaneous semaglutide type 2 diabetes safety Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	glucagon-like peptide-1 receptor agonist (GLP-1RA) oral subcutaneous semaglutide type 2 diabetes safety Diseases of the endocrine glands. Clinical endocrinology RC648-665 Mark M. Smits Daniël H. Van Raalte Safety of Semaglutide
description	The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide InnOvatioN for the Early diabEtes tReatment) semaglutide and are being studied in further trials and registries, including real world data studies. In the current review we discuss the occurrence of adverse events associated with semaglutide focusing on hypoglycemia, gastrointestinal side effects, pancreatic safety (pancreatitis and pancreatic cancer), thyroid cancer, gallbladder events, cardiovascular aspects, acute kidney injury, diabetic retinopathy (DRP) complications and injection-site and allergic reactions and where available, we highlight potential underlying mechanisms. Furthermore, we discuss whether effects are specific for semaglutide or a class effect. We conclude that semaglutide induces mostly mild-to-moderate and transient gastrointestinal disturbances and increases the risk of biliary disease (cholelithiasis). No unexpected safety issues have arisen to date, and the established safety profile for semaglutide is similar to that of other GLP-1RAs where definitive conclusions for pancreatic and thyroid cancer cannot be drawn at this point due to low incidence of these conditions. Due to its potent glucose-lowering effect, patients at risk for deterioration of existing DRP should be carefully monitored if treated with semaglutide, particularly if also treated with insulin. Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.
format	article
author	Mark M. Smits Daniël H. Van Raalte
author_facet	Mark M. Smits Daniël H. Van Raalte
author_sort	Mark M. Smits
title	Safety of Semaglutide
title_short	Safety of Semaglutide
title_full	Safety of Semaglutide
title_fullStr	Safety of Semaglutide
title_full_unstemmed	Safety of Semaglutide
title_sort	safety of semaglutide
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c006b197be31425dac88ecfb77dea26f
work_keys_str_mv	AT markmsmits safetyofsemaglutide AT danielhvanraalte safetyofsemaglutide
_version_	1718439912871559168

Safety of Semaglutide

Ejemplares similares